PDEX (Pro-Dex) YoY EBITDA Growth: 17.96% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PDEX Pro-Dex Inc PDEX
69 GF Score
Price $66.42
GF Value $40.81
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Pro-Dex YoY EBITDA Growth?

Pro-Dex PDEX -0.50% 69 YoY EBITDA Growth is 17.96% as of Mar. 2026. GuruFocus rates PDEX with a GF Score™ of 69/100 and a GF Value™ of $40.81 (Significantly Overvalued). The stock has 9 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Pro-Dex's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 17.96%.

Pro-Dex's EBITDA per Share for the three months ended in Mar. 2026 was $1.81.

Pro-Dex YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Pro-Dex's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pro-Dex YoY EBITDA Growth Chart

Pro-Dex Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 -16.83 62.60 -59.01 244.79

Pro-Dex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.96 -6.99 75.92 10.11 17.96
PDEX
69GF Score
Pro-Dex Inc PDEX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pro-Dex YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Pro-Dex's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(4.203-1.219)/ | 1.219 |
=244.79 %

Pro-Dex's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(1.806-1.531)/ | 1.531 |
=17.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 17.96% mean?
Pro-Dex (PDEX) has a YoY EBITDA Growth of 17.96% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Pro-Dex and its competitors.
Is Pro-Dex's YoY EBITDA Growth too high?
Pro-Dex's current YoY EBITDA Growth is 17.96%. Overall, Pro-Dex has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's YoY EBITDA Growth compare to KRMD and EMBC?
Pro-Dex's YoY EBITDA Growth of 17.96% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Pro-Dex and its competitors. Pro-Dex's current YoY EBITDA Growth is 17.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (PDEX) is currently considered Significantly Overvalued. The stock's GF Value™ is $40.81, compared to a current price of $66.42 — trading 62.8% above its estimated fair value. The current YoY EBITDA Growth is 17.96%. Pro-Dex's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Pro-Dex (PDEX), the current YoY EBITDA Growth is 17.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pro-Dex (PDEX) Overvalued in 2026?

Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued. The current stock price of $66.42 is trading 62.8% above its estimated GF Value™ of $40.81. GuruFocus considers Pro-Dex to be Significantly Overvalued.

Key valuation signals for PDEX:

  • YoY EBITDA Growth: 17.96%
  • GF Value™: $40.81 vs. price of $66.42 (62.8% above fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the PDEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pro-Dex Business Description

Other Exchanges PDXN:Germany
Address 2361 McGaw Avenue, Irvine, CA, USA, 92614
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
69GF Score

Get the complete analysis for PDEX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.42
Price
$40.81
GF Value